

Our promise

Our commitment to Quality, Reliability and Sustainability is at the heart of everything we do.

Quality

Driving Quality to the next level

Our proprietary enzymatic platform along with our world-class, high-quality active pharmaceutical ingredients and finished dosage forms deliver tangible value to customers, such as high purity, use efficiency and favourable storage parameters.

Reliability


Our promise delivered

With over 75 years of experience in antibiotics, we are a well-established trusted business partner. We produce our key intermediates in-house. Our global backward integrated manufacturing setup safeguards security of supply for our customers.

Sustainability

Leading the way

Centrient a founding member of the AMR Industry Alliance - uniting the antibiotics industry in the fight against antimicrobial resistance -, and a member of the Pharmaceutical Supply Chain Initiative (PSCI) and Medicines for Europe to help drive sustainable supply chains for medicines and increase access to antibiotics as essential medicines.



About Centrient Pharmaceuticals

Centrient Pharmaceuticals (Centrient) is the global business-to-business leader in sustainable, enzymatic antibiotics, next-generation statins, and anti-fungals. We are a pharmaceutical company with a clear purpose: to improve lives through innovative and sustainable manufacturing of medicines - saving the lives of millions of people around the world annually.

We produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as finished dosage forms (FDFs). Driven by our Purpose and Sustainability through our Environmental, Social and Governance (ESG) Vision, we aim to create value for Centrient and our stakeholders.

Headquartered in Rijswijk, the Netherlands, Centrient has production facilities and sales offices in China, India, the Netherlands, Spain, the United States and Mexico. Centrient is owned by Bain Capital Private Equity, a leading global private investment firm.

Contact and information

For more information, please visit centrient.com or email licensing@centrient.com

Copyright © 2022 Centrient Pharmaceuticals. All rights reserved.

Although all reasonable and diligent care has been used to ensure that the information provided herein is accurate, nothing contained herein shall, or may, be construed to imply any representation or warranty as to the accuracy, currency or completeness of this information nor shall it be construed to imply any other representation or warranty of any kind, including the implied warranties of merchantability, fitness for a particular purpose or non-infringement. Centrient has no obligation to update the statements contained in this presentation, unless required by applicable law. The content of this document is subject to change without any notice. Product offers are explicitly not made in respect of those jurisdictions where valid third party patent rights related to such products are in force. In such jurisdictions the advertised products are only offered for regulatory purposes insofar allowed under local provisions such as the Bolar provisions in the US and 2004/27/EC in Europe.
VGL03102022



Finished Dosage Forms Portfolio



Why work with Centrient Pharmaceuticals?

Your success is our success

Centrient Pharmaceuticals is a business-to-business provider of generics FDFs, not marketing the products ourselves. Therefore, we do not compete with our customers in the end market. All our dossiers are readily available for out-licensing to our partners worldwide.

European-based production facilities and supply chain

We work primarily with Europe-based FDFs manufacturers. Customers can be confident that the origin, traceability, and quality of our products are impeccable. We offer a dual sourcing strategy and procurement excellence for our third-party-produced APIs.

Proactive QA, RA and artwork services

With our extensive regulatory and quality assurance know-how and services, doing business with us enables you to focus on what truly counts: your business and your customers.

Reliable supply chain via backward integration

We provide intermediates, active pharmaceutical ingredients (APIs) and finished dosage forms based on our backward integrated global manufacturing capabilities. As a member of the Pharmaceutical Supply Chain Initiative, we ensure our supply chain is of the highest standards.

Leading the way in responsible production

We operate dedicated wastewater treatments plants 24/7/365 at our manufacturing sites and apply antimicrobial activity testing to ensure disposed water is clean.

PureActives® – the enzymatic difference

Our patented enzymatic platform completely replaces the traditional 13-step antibiotic production process with natural processes that eliminate the use of solvents or other chemicals.

Our Finished Dosage Forms Portfolio



Molecule	Dosage form	Strength	EU-CTD*	Climatic Zone IV
Beta-lactam Antibiotics 				
Amoxicillin	 Hard capsule	500 mg	✓	-
	 Tablet (Dispersible)	500 mg 750 mg 1,000 mg	✓	-
	 Powder for oral suspension	125 mg / 5 ml 250 mg / 5 ml 500 mg / 5 ml	✓	-
Amoxicillin + Clavulanic acid	 Film-coated tablet	250 mg + 125 mg (2:1) 500 mg + 125 mg (4:1) 875 mg + 125 mg (7:1)	✓	ongoing
		500 mg + 62.5 mg (8:1)		-
	 Powder for oral suspension	125 mg + 31.25 mg (4:1) / 5ml 250 mg + 62.5 mg (4:1) / 5ml 400 mg + 57 mg (7:1) / 5ml 600 mg + 42.9 mg (14:1) / 5ml	✓	✓
		200 mg + 28.5 mg (7:1) / 5ml	✓	under development
500 mg + 62.5 mg (8:1) / 5ml		✓	-	
 Powder for oral suspension in sachet	500 mg + 125 mg (4:1) 875 mg + 125 mg (7:1) 1,000 mg + 125 mg (8:1)	✓	-	
Statins				
Atorvastatin	 Film-coated tablet	10 mg 20 mg 40 mg 80 mg	✓	✓
		30mg 60mg	✓	-
Rosuvastatin	 Film-coated tablet	5 mg 10 mg 20 mg 40 mg	✓	✓
Anti-Fungals				
Caspofungin	 Powder concentrate for infusion solution	50 mg 70 mg	✓	NA – Cold Chain

*Dossiers available for world-wide filing. Availability of dossiers is dependent on local regulatory requirements